

Supplementary Information

Light-driven decarboxylative deuteration enabled by a divergently engineered photodecarboxylase

Jian Xu^{1,2,4*}, Jiajie Fan^{1,4}, Yujiao Lou^{1,4}, Weihua Xu^{1,4}, Zhiguo Wang^{3,4}, Danyang Li¹, Haonan Zhou¹, Xianfu Lin¹
& Qi Wu^{1*}

¹ Center of Chemistry for Frontier Technologies, Department of Chemistry, Zhejiang University, Hangzhou, 310027, P. R. China. *e-mail: wuqi1000@163.com or llc123@zju.edu.cn.

² College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, 310014, P. R. China. *e-mail: jianxu@zjut.edu.cn.

³ Institute of Aging Research, School of Medicine, Hangzhou Normal University, Hangzhou, 311121, P. R. China.

⁴ These authors contributed equally.

Supplementary Figures


<i>Supplementary Fig. 1. Dependence of cosolvent in the CvFAP catalyzed decarboxylative deuteration.</i>	3
<i>Supplementary Fig. 2. The effect of substrate concentration on the CvFAP catalyzed decarboxylative deuteration.</i>	4
<i>Supplementary Fig. 3. The progress curve of CvFAP catalyzed decarboxylative deuteration.</i>	5
<i>Supplementary Fig. 4. Effect of water content in the enzyme system on the D- incorporation.</i>	6
<i>Supplementary Fig. 5. Screening results of the FRISM library using the model decarboxylation of nonanoic acid.</i>	7
<i>Supplementary Fig. 6. Recovered times of D₂O in the CvFAP catalyzed decarboxylative deuteration.</i>	8
<i>Supplementary Fig. 7. SDS-PAGE of WT-CvFAP and mutants.</i>	9
<i>Supplementary Fig. 8. Derivatization of 5d to (+)-Igmisine-d₁ with reported methods.</i>	10
<i>Supplementary Fig. 9-14. Comparison of the distance between the carboxyl of substrates and the N5 atom of FAD in variants by MD simulation.</i>	11-16
<i>Supplementary Fig. 15-25. Chiral GC chromatogram of the enantioselective decarboxylative deuteration of 4a-4k.</i>	17-27
<i>Supplementary Fig. 26. NMR spectra of 2-(Hexadecyloxy)acetic acid (1I).</i>	28
<i>Supplementary Fig. 27. NMR spectra of 2-(Dodecyloxy)acetic acid (2K).</i>	29
<i>Supplementary Fig. 28-36. NMR spectra of 4A-4I.</i>	30-38
<i>Supplementary Fig. 37-47. NMR (or/and HRMS) spectra of 1a-1k.</i>	39-56
<i>Supplementary Fig. 48-58. NMR (or/and HRMS) spectra of 2a-2k.</i>	57-71
<i>Supplementary Fig. 59-66. HRMS spectra of 3a-3h.</i>	72-79
<i>Supplementary Fig. 67-77. NMR (or/and HRMS) spectra of 4a-4k.</i>	80-90
<i>Supplementary Fig. 78-88. NMR (or/and HRMS) spectra of 5a-5k.</i>	91-103

Supplementary Tables


<i>Supplementary Table 1 List of primers.</i>	104
<i>Supplementary Table 2 The ratio of M-1 peak to M peak in HRMS of various hydrocarbons with low boiling points.</i>	105
<i>Supplementary Table 3 Evaluation of the difference of D-incorporation determined by NMR and HRMS.</i>	106
<i>Supplementary Table 4 Protein sequence of CvFAP.</i>	107
<i>Supplementary Table 5 DNA sequence of CvFAP.</i>	108
<i>Supplementary Table 6 Characterization data of prepared substrates and products.</i>	109

Supplementary References	117
---------------------------------	-----

Supplementary Figures




Supplementary Fig. 1. Dependence of cosolvent in the CvFAP catalyzed decarboxylative deuteration. Reaction conditions: palmitic acid (0.40 mmol), crude enzyme powder (containing CvFAP about 20 mg), D₂O (4 mL), cosolvent (1 mL), 450 nm LED, 20 °C, 2 h, yields are determined by GC.




Supplementary Fig. 2. The effect of substrate concentration on the CvFAP catalyzed decarboxylative deuteration.


Reaction conditions: palmitic acid (1-100 mM), crude enzyme powder (containing CvFAP about 20 mg), D₂O (4 mL), DMSO (1 mL), 450 nm LED, 20°C, 2 h. Yields are determined by GC.



Supplementary Fig. 3. The progress curve of CvFAP catalyzed decarboxylative deuteration. Reaction conditions: palmitic acid (100 mM), crude enzyme powder (containing CvFAP about 20 mg), D₂O (4 mL), DMSO (1 mL), 450 nm LED, 20 °C, 1-16 h, yields are determined by GC.




Supplementary Fig. 4. Effect of water content in the enzyme system on the D- incorporation. a) the D- incorporation of **1a** obtained from WT CvFAP treated with different freeze-drying time. b) the D- incorporation of **1c** obtained from WT CvFAP treated with different freeze-drying time. c) Effect of water content in WT CvFAP on the D- incorporation of **1a**. Reaction conditions: substrate (0.40 mmol), crude enzyme powder (containing CvFAP about 20 mg), D₂O (4 mL), DMSO (1 mL), 450 nm LED, 20 °C, 12 h, yields are determined by GC. D-inc. data are determined by ¹H NMR or HRMS.




Supplementary Fig. 5. Screening results of the FRISM library using the model decarboxylation of nonanoic acid.


Reaction conditions: nonanoic acid (0.02 mmol), 1 mL crude enzyme solutions of different mutants (1 g wet cell in 10 mL pH 8.5 phosphate buffer), DMSO (0.2 mL), 450 nm LED, 20 °C, 12 h, yields are determined by GC.




Supplementary Fig. 6. Recovered times of D₂O in the CvFAP catalyzed decarboxylative deuteration. D₂O was recovered by vacuum distillation. Reaction conditions: palmitic acid (100 mM), crude enzyme powder (containing CvFAP about 20 mg), D₂O (4 mL), DMSO (1 mL), 450 nm LED, 20 °C, 12 h, yield is determined by GC, D-inc. was determined by HRMS.




Supplementary Fig. 7 SDS-PAGE of WT-CvFAP and mutants expressed in *E. coli*. Lane 1 and 8: protein markers. Lane 2-7: cell extract of WT CvFAP, I398L, G462A, I398R, G462F, and Y466A. Lane 9-14: protein of WT CvFAP, I398L, G462A, I398R, G462F, and Y466A after purification. Three experiment was repeated independently with similar results.




Supplementary Fig. 8. Derivatization of 5d to (+)-Igmesine-*d*₁ with reported methods.^{1,2} Reagents and conditions: a) whole-cell culture medium of ketoreductase with glucose, 30 °C, over night; b) $i\text{Pr}_2\text{NCOCl}$ (1.05 equiv), NEt_3 (1.1 equiv), CH_2Cl_2 , reflux, 24 h; c) *sec*-butyllithium (1.1 equiv), -78°C , 20 min; then cinnamyl boronic acid pinacol ester (1.2 equiv), -78°C , 1 h; then 1M MgBr_2 in MeOH (1.2 equiv), -78°C , 10 min, then RT, 16 h; then 1M aq KH_2PO_4 ; d) 4.5m aq KHF_2 (2.5 equiv), MeOH, RT, 30 min, evaporation; then 50% aq MeOH, 10 min and evaporation (5x); e) SiCl_4 , (2 equiv), DCE, RT, 1 h; $c\text{PrCH}_2\text{N}_3$ (2 equiv), 80°C , 30 min; then 2M aq NaOH, RT, 1 h; f) 37% aq CH_2O , NaHB(OAc)_3 , DCE, RT, 16 h.




Supplementary Fig. 9. Comparison of the distance between the carboxyl of nonanoic acid (2A) and the N5 atom of FAD in WT-CvFAP and I398L by MD simulation.




Supplementary Fig. 10. Comparison of the distance between the carboxyl of propionic acid (3A) and the N5 atom of FAD in WT-CvFAP and G462A by MD simulation.




Supplementary Fig. 11. Comparison of the distance between the carboxyl of (*R*)- and (*S*)- 2-(heptan-3-yloxy) acetic acid (4A) and the N5 atom of FAD in I398R by MD simulation.




Supplementary Fig. 12. Comparison of the distance between the carboxyl of (*R*)- and (*S*)- 2-(heptan-3-yloxy) acetic acid (4A) and the N5 atom of FAD in G462F by MD simulation.



Supplementary Fig. 13. Comparison of the distance between the carboxyl of (*S*)- 3-phenylbutanoic acid ((*S*)-5A) and the N5 atom of FAD in WT-C ν FAP and Y466A by MD simulation.




Supplementary Fig. 14. Comparison of the distance between the carboxyl of (*R*)- 3-phenylbutanoic acid (*(R)*-5A) and the N5 atom of FAD in WT-CvFAP and Y466A by MD simulation.




Supplementary Fig. 15. Chiral GC chromatogram of the enantioselective decarboxylative deuteration of 4a.

Agilent CP-chirasil-Dex CB, $T_R = 12.47$ min, $T_S = 12.87$ min, Temperature conditions: initial temperature 40 °C, holding 15 min, then 40 °C/min to 200 °C, holding 1 min.




Supplementary Fig. 16. Chiral GC chromatogram of the enantioselective decarboxylative deuteration of 4b.

Agilent CP-chirasil-Dex CB, $T_R = 17.52$ min, $T_S = 18.19$ min, Temperature conditions: initial temperature 40 °C, holding 20 min, then 40 °C/min to 200 °C, holding 1 min




Supplementary Fig. 17. Chiral GC chromatogram of the enantioselective decarboxylative deuteration of 4c.

Agilent CP-chirasil-Dex CB, $T_R = 20.21$ min, $T_S = 20.75$ min, Temperature conditions: initial temperature 50 °C, holding 22 min, then 40 °C/min to 200 °C, holding 1 min.




Supplementary Fig. 18. Chiral GC chromatogram of the enantioselective decarboxylative deuteration of 4d.

Agilent CP-chirasil-Dex CB, $T_R = 14.77$ min, $T_S = 15.46$ min, Temperature conditions: initial temperature 40 °C, holding 20 min, then 40 °C/min to 200 °C, holding 1 min.




Supplementary Fig. 19. Chiral GC chromatogram of the enantioselective decarboxylative deuteration of 4E.

Agilent CP-chirasil-Dex CB, $T_R = 10.58$ min, $T_S = 10.79$ min, Temperature conditions: initial temperature 100 °C, 2 °C/min to 130 °C, then 35 °C/min to 200 °C, holding 1 min. The e.r. value of **4E** was determined after the sulfuric acid-catalyzed derivatization with methyl alcohol, and the e.r. value of **4e** was calculated based on the conversion and e.r. of **4E**.




Supplementary Fig. 20. Chiral GC chromatogram of the enantioselective decarboxylative deuteration of 4f.

Agilent CP-chirasil-Dex CB, $T_R = 11.91$ min, $T_S = 12.16$ min, Temperature conditions: initial temperature 40 °C, holding 7 min, 1 °C /min to 50 °C, then 50 °C /min to 200 °C, holding 1 min.




Supplementary Fig. 21. Chiral GC chromatogram of the enantioselective decarboxylative deuteration of 4g.

Agilent CP-chirasil-Dex CB, $T_R = 12.47$ min, $T_S = 12.87$ min, Temperature conditions: initial temperature 40 °C, holding 15 min, then 40 °C /min to 200 °C, holding 1 min.




Supplementary Fig. 22. Chiral GC chromatogram of the enantioselective decarboxylative deuteration of 4h.

Agilent CP-chirasil-Dex CB, $T_R = 17.53$ min, $T_S = 18.20$ min, Temperature conditions: initial temperature 40 °C, holding 20 min, then 40 °C /min to 200 °C, holding 1 min.




Supplementary Fig. 23. Chiral GC chromatogram of the enantioselective decarboxylative deuteration of 4i. Agilent CP-chirasil-Dex CB, $T_R = 19.78$ min, $T_S = 20.73$ min, Temperature conditions: initial temperature 50 °C, holding 8 min, then 50 °C /min to 200 °C, holding 1 min.





Supplementary Fig. 24. Chiral GC chromatogram of the enantioselective decarboxylative deuteration of 4j.

Agilent CP-chirasil-Dex CB, $T_R = 15.24$ min, $T_S = 15.67$ min, Temperature conditions: initial temperature 80 °C, holding 5 min, 2 °C /min to 110 °C, then 45 °C /min to 200 °C, holding 1 min. The e.r. value of 4j were determined after the derivatization with butyryl chloride.





Supplementary Fig. 25. Chiral GC chromatogram of the enantioselective decarboxylative deuteration of 4k.



Agilent CP-chirasil-Dex CB, $T_R = 31.73$ min, $T_S = 32.11$ min. Temperature conditions: initial temperature 80 °C, holding 5 min, 5 °C /min to 160 °C, then 40 °C /min to 200 °C, holding 1 min. The e.r. value of **4k** were determined after the derivatization with butyryl chloride.





Supplementary Fig. 26. NMR spectra of 2-(Hexadecyloxy)acetic acid (II).





Supplementary Fig. 27. NMR spectra of 2-(Dodecyloxy)acetic acid (2K).





Supplementary Fig. 28. NMR spectra of 2-(Heptan-3-yloxy)acetic acid (4A).





Supplementary Fig. 29. NMR spectra of 2-(Octan-2-yloxy)acetic acid (4B).





Supplementary Fig. 30. NMR spectra of 2-(Oct-1-en-3-yloxy)acetic acid (4C).





Supplementary Fig. 31. NMR spectra of 2-(heptan-2-yloxy)acetic acid (4D).





Supplementary Fig. 32. NMR spectra of 2-((6-Methylheptan-2-yl)oxy)acetic acid (4E).





Supplementary Fig. 33. NMR spectra of 2-((2-Methylhexan-3-yl)oxy)acetic acid (4F).





Supplementary Fig. 34. NMR spectra of 2-(Heptan-3-yloxy)acetic-2,2-d₂ acid (4G).




Supplementary Fig. 35. NMR spectra of 2-(Octan-2-yloxy)acetic-2,2-d₂ acid (4H).






Supplementary Fig. 36. NMR spectra of 2-(Oct-1-yn-3-yloxy)acetic acid (4I).








Supplementary Fig. 37. NMR and HRMS spectra of Pentadecane-1-d (1a). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.







Supplementary Fig. 38. NMR and HRMS spectra of Heptadecane-1-d (1b). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.








Mass	RA	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
254.2968	5.11	254.2974	-0.6	-2.4	0.0	2774185.8	C18 1H38
255.3038	100.00	255.3036	0.2	0.8	0.0	5547164.0	C18 1H37 2H

Supplementary Fig. 39. NMR and HRMS spectra of Octadecane-1-d (**1c**). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.






Supplementary Fig. 40. NMR spectra of (Z)-Heptadec-8-ene-1-d (**1d**). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.







Supplementary Fig. 41. NMR and HRMS spectra of (E)-Heptadec-8-ene-1-d (1e). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.








Supplementary Fig. 42. NMR and HRMS spectra of (6Z,9Z)-Heptadeca-6,9-diene-17-d (**1f**). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.





Supplementary Fig. 43. NMR spectra of Heptadecan-17-d-7-ol (1g). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.








Supplementary Fig. 44. NMR and HRMS spectra of Methyl tetradecanoate-14-d (1h). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.





Supplementary Fig. 45. NMR spectra of 1-(Methoxy-d)hexadecane (1i**).** The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.







Supplementary Fig. 46. NMR and HRMS spectra of Tridecane-1,13-d2 (1j). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.







Supplementary Fig. 47. NMR spectra of Heptadecan-7-yl-17-d acetate (**1k**). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.




2a





Supplementary Fig. 48. HRMS spectrum of Octane-1-d (2a).








Supplementary Fig. 49. NMR and HRMS spectra of Undecane-1-d (2b). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.





Supplementary Fig. 50. NMR spectra of Decan-10-d-1-ol (2c). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.







Supplementary Fig. 51. NMR and HRMS spectra of 1-Bromodecane-10-d (2d). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.





Supplementary Fig. 52. NMR spectra of Heptan-7-d-1-ol (2e). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.





2f





Supplementary Fig. 53. HRMS spectrum of Heptane-1,7-d2 (2f).




Supplementary Fig. 54. NMR spectra of tert-Butyl (pentyl-5-d)carbamate (2g). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.






Supplementary Fig. 55. NMR spectra of Decyl-10-d acetate (2h**).** The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.







Supplementary Fig. 56. NMR and HRMS spectra of Methyl octanoate-8-d (2i). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.









Supplementary Fig. 57. NMR and HRMS spectra of Dec-1-ene-10-d (2j). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.



Supplementary Fig. 58. NMR spectra of 1-(Methoxy-d)dodecane (2k**).** The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.




Supplementary Fig. 59. HRMS spectra of Ethane-d (3a) and Ethane without deuterium.



Supplementary Fig. 60. HRMS spectra of Hexane-1-d (3b) and Hexane without deuterium.





3c




Mass	RA	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
92.0390	20.77	92.0393	-0.3	-3.3	0.0	2773768.5	C4 1H9 Cl
93.0453	100.00	93.0456	-0.3	-3.2	0.0	5546658.5	C4 1H8 2H Cl

Supplementary Fig. 61. HRMS spectrum of 1-Chlorobutane-4-d (3c).




Minimum:	2.00							
Maximum:	100.00		1.0	10.0	-1.5			50.0
Mass	RA	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula	
115.0549	6.67	115.0548	0.1	0.9	6.5	5546025.5	C9 H7	
115.1475	100.00	115.1471	0.4	3.5	0.0	2773019.0	C8 H17 2H	



Supplementary Fig. 62. HRMS spectrum of 2, 2, 4-Trimethylpentane-5-d (3d).





3e





Supplementary Fig. 63. HRMS spectrum of Butan-2-one-4-d (3e).




Supplementary Fig. 64. HRMS spectra of Propane-1-d (3f) and Propane without deuterium.





Supplementary Fig. 65. HRMS spectra of But-1-ene-4-d (3g) and Butene without deuterium.





Supplementary Fig. 66. HRMS spectra of Isobutane-1-d (3h) and Isobutane without deuterium.





Supplementary Fig. 67. NMR spectra of 3-(Methoxy-d)heptane (4a). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.





Supplementary Fig. 68. NMR spectra of 2-(Methoxy-d)octane (**4b**). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.





Supplementary Fig. 69. NMR spectra of 3-(Methoxy-d)oct-1-ene (**4c**). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.





Supplementary Fig. 70. NMR spectra of 2-(Methoxy-d)heptane (4d). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.





Supplementary Fig. 71. NMR spectra of 2-(Methoxy-d)-6-methylheptane (4e). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.



Supplementary Fig. 72. NMR spectra of 3-(Methoxy-d)-2-methylhexane (**4f**). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.




Supplementary Fig. 73. NMR spectra of 3-(Methoxy-d₃)heptane (**4g**). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.




Supplementary Fig. 74. NMR spectra of 2-(Methoxy-d₃)octane (**4h**). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.

0730L2 244 (1.047)
TOF MS EI+




Mass	RA	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
139.1140	2.66	139.1123	1.7	12.2	2.5	229.9	C9 H15 O
140.1206	100.00	140.1201	0.5	3.6	2.0	2773014.3	C9 H16 O
141.1252	9.68	141.1264	-1.2	-8.5	2.0	5546026.5	C9 H15 2H O
144.9987	3.39	---	---	---	---	---	---

0730L1 251 (1.073)
TOF MS EI+





Mass	RA	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
139.1133	100.00	139.1123	1.0	7.2	2.5	3.9	C9 H15 O
140.1206	11.78	140.1201	0.5	3.6	2.0	2773012.5	C9 H16 O



Supplementary Fig. 75. HRMS spectra of 3-(Methoxy-d)oct-1-yne (4i) and the corresponding 3-(Methoxy)oct-1-yne without deuterium. The D-incorporation of 4i was determined by the comparison of HRMS between the H- and D-4i.




Supplementary Fig. 76. NMR spectra of Octan-8-d-4-ol (4j). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.





Supplementary Fig. 77. NMR spectra of Undecan-1-d-4-ol (4k). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.








Supplementary Fig. 78. NMR and HRMS spectra of (Propan-2-yl-1-d)benzene (5a). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.





Supplementary Fig. 79. NMR spectra of (Propyl-2-d)benzene (5b**).** The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.








Supplementary Fig. 80. NMR and HRMS spectra of (Propyl-3-d)benzene (5c). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.




Supplementary Fig. S1. NMR spectra of 1-Phenyl-1-propanone-3-d (5d**). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.**



Supplementary Fig. S2. NMR spectra of 1-(4-Fluorophenyl)butan-1-one-4-d (**5e**). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.




5f




Mass	RA	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
98.1095	2.93	98.1065	3.0	30.6	2.0	0.2	C7 H10 2H2
		98.1080	1.5	15.3	1.5	127.9	C7 H12 2H
		98.1096	-0.1	-1.0	1.0	2773135.8	C7 H14
99.1188	100.00	99.1158	3.0	30.3	1.0	2773035.8	C7 H13 2H
		99.1174	1.4	14.1	0.5	5546091.5	C7 H15



Supplementary Fig. 83. HRMS spectrum of Methylcyclohexane-1-d (5f).





5g




Supplementary Fig. 84. HRMS spectrum of (Methyl-d)cyclohexane (5g).




Supplementary Fig. 85. NMR spectra of 1,4-dimethyl-2-((4-methylpentyl-4-d)oxy)benzene (**5h**). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view.



Supplementary Fig. 86. NMR spectra of (E)-7-hydroxy-5-methoxy-4-methyl-6-(3-methylpent-2-en-1-yl)-5-d)isobenzofuran-1(3H)-one (5i). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.



Supplementary Fig. 87. NMR spectra of 2-(ethyl-1-d)dibenzo[b,f]thiepin-10(11H)-one (**5j**). The splitting of C-D coupling in ^{13}C -NMR was shown with an enlarged view. The signal at δ 4.34 for two protons on C11 (labeled with star) shows reduced intensity, indicating some deuteration also occurs at this position due to tautomeric exchange of the substrate with the solvent. The D-inc. on C11 of **5j** was 66% according to the signal intensity at δ 4.34.



Supplementary Fig. 88. NMR spectra of (4a*S*,10a*S*)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-d (**5k**). The splitting of C-D coupling in ¹³C-NMR was shown with an enlarged view.

Supplementary Tables

Supplementary Table 1 List of primers.

Mutant	Sequence
A128L	GTAAAAATTCCGCTGGCAATTACCCG
A128F	GTAAAAATTCCGTTTGCAATTACCCG
A171L	TAGCAGCGCAACCAATCTGACCCTGTATCATCG
A171F	TAGCAGCG CAACCAATTTTACCCTGTATCATCG
T172A	GCAACCAATGCAGCGCTGTATCATCG
T172L	GCAACCAATGCACIGCTGTATCATCG
T172F	GCAACCAATGCATTICTGTATCATCG
I398A	AAATATGATGGTGCCGCCATCAGCGATCAC
I398L	AAATATGATGGTCTGGGCCATCAGCGATCAC
I398F	AAATATGATGGTTTTGGCCATCAGCGATCAC
I398R	AAATATGATGGTCCGCCGCCATCAGCGATCAC
A399L	TATGATGGTATTCTGATCAGCGATCACATT
A399F	TATGATGGTATTTTATCAGCGATCACATT
G431A	CTGACCAGTACCGCGTGTGATCGTGG
G431L	CTGACCAGTACCCTGTGTGATCGTGG
G431F	CTGACCAGTACCTTTTGTGATCGTG
G462A	CTGGATCCGGATGCGGTTAGCACCTATG
G462L	CTGGATCCGGATCTGGTTAGCACCTATG
G462F	CTGGATCCGGATTTTGTAGCACCTATG
Y466A	GATGGTGTTAGCACCGCGTTCGTTTTGCAAAA
Y466L	GATGGTGTTAGCACCTGGTTCGTTTTGCAAAA
Y466F	GATGGTGTTAGCACCTTTGTTTCGTTTTGCAAAA
Q486A	GTATTACCATGGCGCTGATTGCATG
Q486L	GTATTACCATGCTGCTGATTGCATG
Q486F	GTATTACCATGTTICTGATTGCATG
silent reverse primer	GATGCCGGGAGCAGACAAGCCCGTCAGGGCGC

Supplementary Table 2 The ratio of M-1 peak to M peak in HRMS of various hydrocarbons with low boiling points.

Substrate	HRMS result	
	Ratio _M (%)	Ratio _{M-1} (%)
Ethane	100	66
Propane	100	80
Pentane	100	12
Hexane	100	2
Heptane	100	<1
Octane	100	<1
Decane	100	<1
Undecane	100	<1

Supplementary Table 3 Evaluation of the difference of D-incorporation determined by NMR and HRMS.

Substrate	D-incorporation (%)	
	Determined by HRMS	Determined by NMR
1a	91±1	93±2
1b	94±2	95±2
1c	95±1	96±1

Data are presented as mean value ± SD (standard deviations) of three replicates.









Supplementary Table 4 Protein sequence of CvFAP.









Protein sequence of CvFAP					
MGSSHHHHH	SSGLVPRGSH	MASMTGGQQM	GRGSEFMASI	TSRASARASC	SQANTRAGRV
ALSGGALLRP	ARPARSFVPA	RKQQQGAVRR	GGALSARASA	VEDIRKVLSD	SSSPVAGQKY
DYILVGGGTA	ACVLANRLSA	DGSKRVLVLE	AGPDNTRSDV	KIPAAITRLF	RSPLDWNLFS
ELQEQLAERQ	IYMARGRLLG	GSSATNATLY	HRGAAGDYDA	WGVEGWSSSED	VLSWVQAET
NADFGPGAYH	GSGGPMRVEN	PRYTNKQLHT	AFFKAAEEVG	LTPNSDFNDW	SHDHAGYGTF
QVMQDKGTRA	DMYRQYLKPV	LGRRLNLQVLT	GAAVTKVNID	QAAGKAQALG	VEFSTDGPTG
ERLSAELAPG	GEVIMCAGAV	HTPFLKHS	VGPSAELKEF	GIPVVSNLG	VGQNLQDQPA
CLTAAPVKEK	YDGLAISDHI	YNEKGQIRKR	AIASYLLGGR	GGLTSTGCDR	GAFVRTAGQA
LPDLQVRFVP	GMALDPDGVS	TYVRFKQFQS	QGLKWPSGIT	MQLIACRPQS	TGSVGLKSAD
PFAPPKLSPG	YLTDKDGADL	ATLRKGIHWA	RDVARSSALS	EYLDGELFPG	SGVVSDDQID
EYIRRSIHSS	NAITGTCKMG	NAGDSSSVVD	NQLRVHGVEG	LRVVDASVVP	KIPGGQTGAP
VVMIAERAAA	LLTGKATIGA	SAAAPATVAA			









Supplementary Table 5 DNA sequence of CvFAP.









DNA sequence of CvFAP	
1	ATGGGCAGCA GCCATCATCA TCATCATCAC AGCAGCGGCC TGGTGCCGCG CGGCAGCCAT
61	ATGGCTAGCA TGA CTGGTGG ACAGCAAATG GGTCGCGGAT CCGAATTCAT GGCAAGCATT
121	ACCAGCCGTG CAAGCGCACG TGCAAGCTGT AGCCAGGCAA ATACCCGTGC AGGTCGTGTT
181	GCACTGAGCG GTGGTGC ACT GCTGCGTCCG GCACGTCTG CACGTAGCTT TGTTCCGGCA
241	CGTAAACAGC AGCAGGGTGC AGTTCGTCGT GGTGGTGCCC TGAGCGCACG TGCCAGCGCA
301	GTTGAAGATA TTCGTAAAGT TCTGAGCGAT AGCAGCAGTC CGGTTGCAGG TCAGAAATAT
361	GATTATATTC TGGTTGGTGG TGGCACC GCA GCATGTGTTT TGGCAAATCG TCTGAGCGCA
421	GATGGTAGCA AACGTGTTCT GGTTCTGGAA GCAGGTCCGG ATAATACCAG CCGTGATGTT
481	AAAATTCCGG CAGCAATTAC CCGTCTGTTT CGTAGTCCGC TGGATTGGAA CCTGTTTACG
541	GAAGTCAAAG AACAGCTGGC AGAACGTCAG ATTTATATGG CACGTGGTCG TCTGCTGGGT
601	GGTAGCAGCG CAACCAATGC AACCTGTAT CATCGTGGTG CAGCCGGTGA TTATGATGCA
661	TGGGGTGTG AAGTTGGAG CAGCGAAGAT GTTCTGAGCT GGTTTGTTC AAGCAGAAACC
721	AATGCAGATT TTGGTCCGGG TGCATATCAT GGTAGCGGTG GTCCGATGCG TGTTGAAAAT
781	CCGCGTTATA CCAATAAACA GCTGCATACC GCATTTTCA AAGCAGCAGA AGAAGTTGGT
841	CTGACCCCGA ATAGCGATTT TAATGATTGG AGCCATGATC ATGCAGGTTA TGGCACCTTT
901	CAGGTTATGC AGGATAAAGG CACCCGTGCA GATATGTATC GTCAGTATCT GAAACCGGTT
961	CTGGGTCGTC GTAATCTGCA GGTTCTGACC GGTGCAGCAG TTACCAAAGT TAATATTGAT
1021	CAGGCAGCAG GTAAAGCACA GGCAC TGGGT GTTGAATTTT CAACCGATGG TCCGACCGGT
1081	GAACGTCTGA GTGCAGA ACT GGCACCGGGT GGTGAAGTTA TTATGTGTGC CGGTGCAGTT
1141	CATACCCCGT TTCTGCTGAA ACATAGCGGT GTTGGTCCGA GCGCAGAACT GAAAGAATTT
1201	GGTATTCCGG TTGTTAGCAA TCTGGCAGGC GTTGGTCAGA ATCTGCAGGA TCAGCCTGCA
1261	TGTCTGACCG CAGCACCGGT TAAAGAAAAA TATGATGGTA TTGCCATCAG CGATCACATT
1321	TATAACGAAA AAGGTCAGAT TCGCAAACGT GCAATTGCAA GCTATCTGCT GGGAGGTCGT
1381	GGTGGTCTGA CAGTACCGG TTGTGATCGT GGTGCATTG TTCGTACCGC AGGTCAGGCA
1441	CTGCCGGATC TGCAGGTACG TTTTGTCCG GGTATGGCAC TGGATCCGGA TGGTGTTAGC
1501	ACCTATGTTT GTTTTGAAA ATTTAGAGC CAGGGTCTGA AATGGCCGAG CGGTATTACC
1561	ATGCAGCTGA TTGCATGTCG TCCGCAGAGC ACCGGTAGCG TTGGTCTGAA AAGCGCAGAT
1621	CCGTTTGCAC CGCCTAAACT GAGTCCGGT TATCTGACCG ATAAAGATGG TGCAGATCTG
1681	GCAACCCTGC GTAAAGGTAT TCATTGGGCA CGTGATGTTG CACGTAGCAG CGCACTGAGC
1741	GAATATCTGG ATGGTGA ACT GTTCCGGGT AGCGGTGTTG TTAGTGATGA TCAGATTGAT
1801	GAATATATCC GTCGCAGCAT TCATAGCAGC AATGCAATTA CCGGCACCTG TAAAATGGGT
1861	AATGCCGGTG ATAGCAGCAG CGTTGTTGAT AATCAGCTGC GTGTTTATGG TGTGGAAGGT
1921	CTGCGTGTG TTGATGCAAG CGTTGTTCCG AAAATTCCGG GTGGTCAGAC AGGTGCACCG
1981	GTTGTATATG TTGAGAACG TGCAGCAGCA CTGCTGACCG GTAAAGCAAC CATTGGTGCA
2041	AGCGCAGCAG CACCGGCAAC CGTTGCAGCA TGA












Supplementary Table 6 Characterization data of prepared substrates and products.









Compounds	Characterization data
 <p>2-(Hexadecyloxy)acetic acid (1I)</p>	$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 4.09 (s, 2H), 3.57 (t, $J = 6.7$ Hz, 2H), 1.67 – 1.60 (m, 2H), 1.28 (s, 26H), 0.88 (t, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 172.64, 72.23, 67.74, 31.95, 29.71, 29.67, 29.60, 29.56, 29.42, 29.38, 25.91, 22.71, 14.14. HRMS (EI-TOF) m/z : $[\text{M}]^+$ Calcd for $\text{C}_{18}\text{H}_{36}\text{O}_3$ 300.2665; Found 300.2669.
 <p>2-(Dodecyloxy)acetic acid (2K)</p>	$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 4.12 (s, 2H), 3.55 (t, $J = 6.7$ Hz, 2H), 1.72 – 1.57 (m, 2H), 1.26 (m, 18H), 0.88 (t, $J = 6.7$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 174.78, 72.20, 67.73, 31.93, 29.66, 29.64, 29.59, 29.56, 29.43, 29.40, 29.36, 25.91, 22.70, 14.12. HRMS (EI-TOF) m/z : $[\text{M}]^+$ Calcd for $\text{C}_{14}\text{H}_{28}\text{O}_3$ 244.2038; Found 244.2039.
 <p>2-(Heptan-3-yloxy)acetic acid (4A)</p>	$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 4.04 (s, 2H), 3.29 (m, 1H), 1.55 – 1.36 (m, 4H), 1.35 – 1.16 (m, 4H), 0.89 – 0.80 (m, 6H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 173.68, 82.51, 65.85, 32.70, 27.41, 26.02, 22.80, 14.02, 9.36. HRMS (EI-TOF) m/z : $[\text{M}]^+$ Calcd for $\text{C}_9\text{H}_{18}\text{O}_3$ 174.1256; Found 174.1257.
 <p>2-(Octan-2-yloxy)acetic acid (4B)</p>	$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 4.25 – 4.03 (m, 2H), 3.55 (m, 1H), 1.68 – 1.39 (m, 2H), 1.39 – 1.21 (m, 8H), 1.19 (d, $J = 6.1$ Hz, 3H), 0.94 – 0.83 (m, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 174.27, 77.29, 65.48, 36.21, 31.78, 29.32, 25.36, 22.61, 19.32, 14.09. HRMS (EI-TOF) m/z : $[\text{M}]^+$ Calcd for $\text{C}_{10}\text{H}_{20}\text{O}_3$ 188.1412; Found 188.1411.
 <p>2-(Oct-1-en-3-yloxy)acetic acid (4C)</p>	$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 5.65 (ddd, $J = 17.1, 10.2, 8.1$ Hz, 1H), 5.26 (dd, $J = 10.3, 1.6$ Hz, 1H), 5.27 – 5.17 (m, 1H), 4.14 (q, $J = 16.9$ Hz, 2H), 3.76 (m, 1H), 1.77 – 1.48 (m, 2H), 1.41 – 1.29 (m, 6H), 0.92 – 0.85 (m, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 176.07, 137.63, 118.52, 82.56, 64.79, 35.00, 31.65, 24.80, 22.49, 13.93. HRMS (EI-TOF) m/z : $[\text{M}]^+$ Calcd for $\text{C}_{10}\text{H}_{18}\text{O}_3$ 186.1256; Found 186.1253.
 <p>2-(Heptan-2-yloxy)acetic acid (4D)</p>	$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 3.97 (m, 2H), 3.37 (m, 1H), 1.45 – 1.15 (m, 2H), 1.15 – 1.09 (m, 6H), 1.02 (d, $J = 6.2$ Hz, 3H), 0.72 (t, $J = 6.9$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 174.25, 77.29, 65.48, 36.17, 31.83, 25.06, 22.59, 1.32, 14.02. HRMS (EI-TOF) m/z : $[\text{M}]^+$ Calcd for $\text{C}_9\text{H}_{18}\text{O}_3$ 174.1256; Found 174.1259.
 <p>2-((6-Methylheptan-2-yl)oxy)acetic acid (4E)</p>	$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 10.65 (s, 1H), 4.25 – 4.04 (m, 2H), 3.54 (m, 1H), 1.57 (ddt, $J = 26.3, 13.3, 6.6$ Hz, 2H), 1.48 – 1.25 (m, 3H), 1.18 (m, 5H), 0.87 (d, $J = 6.7$ Hz, 6H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 175.73, 76.96, 65.28, 38.89, 36.33, 27.83, 23.07, 22.51, 22.47, 19.12. HRMS (EI-TOF) m/z : $[\text{M}]^+$ Calcd for $\text{C}_{10}\text{H}_{20}\text{O}_3$ 188.1412; Found 188.1409.
	$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 10.41 (s, 1H), 4.07 (d, $J = 2.4$ Hz, 2H), 3.08 (m, 1H), 1.89 – 1.72 (m, 1H), 1.51 – 1.16 (m, 4H), 0.84 (m, 9H).









<p>2-((2-Methylhexan-3-yl)oxy)acetic acid (4F)</p>	<p>^{13}C NMR (100 MHz, CDCl_3) δ 175.43, 86.21, 66.76, 32.21, 30.37, 18.82, 18.12, 17.70, 14.16.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_9\text{H}_{18}\text{O}_3$ 174.1256; Found 174.1255.</p>
<p></p> <p>2-((Heptan-3-yloxy)acetic-2,2-d2 acid (4G)</p>	<p>^1H NMR (400 MHz, CDCl_3) δ 4.10 (m, 0.25H), 3.36 (m, 1H), 1.65 – 1.43 (m, 4H), 1.42 – 1.26 (m, 4H), 0.91 (m, 6H).</p> <p>^{13}C NMR (100 MHz, CDCl_3) δ 174.00, 82.39, 65.53 (t, C-D), 32.70, 27.40, 26.02, 22.81, 14.04, 9.37.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_9\text{H}_{16}\text{D}_2\text{O}_3$ 176.1382; Found 176.1385.</p>
<p></p> <p>2-((Octan-2-yloxy)acetic-2,2-d2 acid (4H)</p>	<p>^1H NMR (400 MHz, CDCl_3) δ 6.91 (s, 1H), 4.00 (m, 0.33H), 3.50 (p, 1H), 1.45 – 1.27 (m, 2H), 1.27 – 1.16 (m, 8H), 1.13 (d, $J = 5.1$ Hz, 3H), 0.89 – 0.76 (m, 3H).</p> <p>^{13}C NMR (100 MHz, CDCl_3) δ 173.03, 76.16, 63.71, 35.23, 30.77, 28.30, 24.34, 21.59, 18.31, 13.06.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_{10}\text{H}_{18}\text{D}_2\text{O}_3$ 190.1538; Found 190.1540.</p>
<p></p> <p>2-((Oct-1-yn-3-yloxy)acetic acid (4I)</p>	<p>^1H NMR (400 MHz, CDCl_3) δ 9.76 (s, 1), 4.50 – 4.01 (m, 3H), 2.43 (d, $J = 2.1$ Hz, 1H), 1.84 – 1.59 (m, 2H), 1.49 – 1.34 (m, 2H), 1.33 – 1.15 (m, 4H), 0.88 – 0.72 (m, 3H).</p> <p>^{13}C NMR (100 MHz, CDCl_3) δ 175.75, 81.40, 75.11, 70.03, 64.91, 35.24, 31.38, 24.66, 22.48, 13.96.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_{10}\text{H}_{16}\text{O}_3$ 184.1099; Found 184.1101.</p>
<p></p> <p>Pentadecane-1-d (1a)</p>	<p>^1H NMR (400 MHz, CDCl_3) δ 1.26 (m, 26H), 0.88 (m, 5H).</p> <p>93% D-inc. calculated from ^1H NMR. 91% D-inc. calculated from HRMS.</p> <p>^{13}C NMR (100 MHz, CDCl_3) δ 31.95, 31.92, 29.73, 29.68, 29.39, 22.72, 22.63, 14.14-13.65(-CH_2-D, -CH_3).</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_{15}\text{H}_{31}\text{D}$ 213.2567; Found 213.2593.</p>
<p></p> <p>Heptadecane-1-d (1b)</p>	<p>^1H NMR (400 MHz, CDCl_3) δ 1.26 (m, 30H), 0.92 – 0.86 (m, 5H).</p> <p>95% D-inc. calculated from ^1H NMR. 94% D-inc. calculated from HRMS.</p> <p>^{13}C NMR (100 MHz, CDCl_3) δ 31.95, 31.92, 29.72, 29.68, 29.39, 22.72, 22.68, 22.63, 14.14-13.65(-CH_2-D, -CH_3).</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_{17}\text{H}_{35}\text{D}$ 241.2880; Found 241.2880.</p>
<p></p> <p>Octadecane-1-d (1c)</p>	<p>^1H NMR (400 MHz, CDCl_3) δ 1.29 – 1.26 (m, 32H), 0.90-0.86 (m, 5H).</p> <p>96% D-inc. calculated from ^1H NMR. 95% D-inc. calculated from HRMS.</p> <p>^{13}C NMR (100 MHz, CDCl_3) δ 31.96, 31.93, 29.74, 29.70, 29.40, 22.72, 22.63, 14.11-13.62 (-CH_2-D, -CH_3).</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_{18}\text{H}_{37}\text{D}$ 255.3036; Found 255.3036.</p>
<p></p> <p>(Z)-Heptadec-8-ene-1-d (1d)</p>	<p>^1H NMR (400 MHz, CDCl_3) δ 5.28 (m, 2H), 1.99 – 1.90 (m, 4H), 1.20 (m, 22H), 0.81 (m, 5H).</p> <p>91% D-inc. calculated from ^1H NMR.</p> <p>^{13}C NMR (100MHz, CDCl_3) δ 128.90, 30.91, 30.86, 28.78, 28.53, 28.32, 28.28, 28.24, 26.20, 21.68, 21.59, 13.10-12.61 (-CH_2-D, -CH_3).</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_{17}\text{H}_{33}\text{D}$ 239.2723; Found 239.2719.</p>
<p></p> <p>(E)-Heptadec-8-ene-1-d (1e)</p>	<p>^1H NMR (400 MHz, CDCl_3) δ 5.38 (m, 2H), 1.96 (q, $J = 6.7$ Hz, 4H), 1.26 (s, 22H), 0.90 – 0.86 (m, 5H).</p> <p>^{13}C NMR (100 MHz, CDCl_3) δ 130.38, 32.63, 31.92, 31.87, 31.61, 29.68, 29.52, 29.34, 29.23, 29.19, 29.15, 22.70, 22.68, 22.61, 14.14-13.64 (-CH_2-D, -CH_3).</p>





	<p>HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₇H₃₃D 239.2723; Found 239.2729.</p> <p>96% D-inc. calculated from HRMS.</p>
 <p>(6Z,9Z)-Heptadeca-6,9-diene-17-d (1f)</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 5.35 (m, 4H), 2.78 (t, <i>J</i> = 6.5 Hz, 2H), 2.05 (q, <i>J</i> = 6.9 Hz, 4H), 1.43 – 1.18 (m, 16H), 0.88 (m, 5H).</p> <p>¹³C NMR (100 MHz, CDCl₃) δ 130.21, 127.97, 31.87, 31.56, 29.71, 29.38, 29.31, 29.25, 27.26, 27.22, 25.64, 22.60, 14.13-13.63 (-CH₂-D, -CH₃).</p> <p>HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₇H₃₁D 237.2567; Found 237.2567.</p> <p>93% D-inc. calculated from HRMS.</p>
 <p>Heptadecan-17-d-7-ol (1g)</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 3.52 (m, 1H), 1.36 (m, 8H), 1.20 (m, 20H), 0.82 (m, 5H).</p> <p>87% D-inc. calculated from ¹H NMR.</p> <p>¹³C NMR (100 MHz, CDCl₃) δ 72.05, 37.51, 31.89, 29.73, 29.64, 29.39, 29.35, 25.67, 25.63, 22.62, 14.09-13.63 (-CH₂-D, -CH₃).</p> <p>HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₇H₃₅DO 257.2829; Found 257.2514.</p>
 <p>Methyl tetradecanoate-14-d (1h)</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 3.67 (s, 3H), 2.30 (t, <i>J</i> = 7.6 Hz, 2H), 1.62 (m, 2H), 1.25 (m, 20H), 0.90 – 0.83 (m, 2H).</p> <p>¹³C NMR (100 MHz, CDCl₃) δ 174.41, 51.47, 34.14, 31.91, 29.69, 29.66, 29.62, 29.47, 29.38, 29.28, 29.17, 24.98, 22.62, 14.03-13.65 (-CH₂-D).</p> <p>HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₅H₂₉DO₂ 243.2309; Found 243.2311.</p> <p>96% D-inc. calculated from HRMS.</p>
 <p>1-(Methoxy-d)hexadecane (1i)</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 3.36 (t, <i>J</i> = 6.6 Hz, 2H), 3.34 – 3.30 (m, 2H), 1.60 – 1.50 (m, 2H), 1.25 (m, 26H), 0.88 (t, <i>J</i> = 6.8 Hz, 3H).</p> <p>96% D-inc. calculated from ¹H NMR.</p> <p>¹³C NMR (100 MHz, CDCl₃) δ 72.97, 58.55-58.04 (-OCH₂-D), 31.94, 29.71, 29.67, 29.62, 29.53, 29.38, 26.16, 22.71, 14.13.</p> <p>HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₇H₃₅DO 257.2829; Found 257.2849.</p>
 <p>Tridecane-1,13-d2 (1j)</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 1.26 (m, 22H), 0.90 – 0.82 (m, 4H).</p> <p>¹³C NMR (100 MHz, CDCl₃) δ 31.92, 29.73, 29.69, 29.40, 22.63, 14.13-13.64 (-CH₂-D).</p> <p>HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₃H₂₇D 185.2254; Found 185.2250.</p> <p>HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₃H₂₆D₂ 186.2317; Found 186.2319.</p> <p>91% 2D-inc. calculated from HRMS.</p>
 <p>Heptadecan-7-yl-17-d acetate (1k)</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 4.79 (m, 1H), 1.97 (s, 3H), 1.43 (m, 4H), 1.19 (s, 24H), 0.81 (t, <i>J</i> = 6.7 Hz, 5H).</p> <p>83% D-inc. calculated from ¹H NMR.</p> <p>¹³C NMR (100 MHz, CDCl₃) δ 170.97, 74.48, 34.13, 31.89, 31.76, 29.61, 29.59, 29.55, 29.34, 29.22, 25.32, 25.28, 22.59, 21.30, 14.06-13.62 (-CH₂-D, -CH₃).</p> <p>HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₉H₃₇DO₂ 299.2935; Found 299.2944.</p>
 <p>Octane-1-d (2a)</p>	<p>HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₈H₁₇D 115.1471; Found 115.1473.</p> <p>98% D-inc. calculated from HRMS.</p>
	<p>¹H NMR (400 MHz, CDCl₃) δ 1.26 (m, 18H), 0.88 (m, 5H).</p> <p>¹³C NMR (100 MHz, CDCl₃) δ 31.95, 31.92, 29.73, 29.68, 29.39, 22.71, 22.63, 14.12-13.64 (-CH₂-D, -CH₃).</p>

<p>Undecane-1-d (2b)</p>	<p>HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₁H₂₃D 157.1941; Found 157.1944. 95% D-inc. calculated from HRMS.</p>
<p> Decan-10-d-1-ol (2c)</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 3.62 (t, <i>J</i> = 6.7 Hz, 2H), 1.96 (m, 1H), 1.55 (m, 2H), 1.27 (m, 14H), 0.92 – 0.81 (m, 2H). 90% D-inc. calculated from ¹H NMR. ¹³C NMR (100 MHz, CDCl₃) δ 62.94, 32.77, 31.90, 31.87, 29.63, 29.57, 29.46, 29.34, 25.76, 22.67, 22.59, 14.08-13.59 (-CH₂-D). HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₀H₂₁DO 159.1733; Found 159.1724.</p>
<p> 1-Bromodecane-10-d (2d)</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 3.40 (t, <i>J</i> = 6.9 Hz, 2H), 1.85 (m, 2H), 1.42 (m, 2H), 1.27 (s, 12H), 0.88 (t, <i>J</i> = 6.8 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 34.01, 32.87, 31.90, 31.87, 29.53, 29.47, 29.32, 28.80, 28.21, 22.69, 22.61, 14.12-13.63 (-CH₂-D). HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₀H₂₀DBr 221.0889; Found 221.0898. 99% D-inc. calculated from HRMS.</p>
<p> Heptan-7-d-1-ol (2e)</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 4.61 (s, 1H), 3.67 (t, <i>J</i> = 6.9 Hz, 2H), 1.55 (p, <i>J</i> = 6.8 Hz, 2H), 1.23 (m, 8H), 0.87 – 0.75 (m, 2H). 87% D-inc. calculated from ¹H NMR. ¹³C NMR (100 MHz, CDCl₃) δ 64.00, 32.01, 31.77, 31.74, 29.02, 25.52, 22.57, 22.49, 14.02-13.53 (-CH₂-D). HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₇H₁₅DO 117.1264; Found 117.1264.</p>
<p> Heptane-1,7-d2 (2f)</p>	<p>HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₇H₁₃D 101.1315; Found 101.1301. HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₇H₁₄D₂ 102.1378; Found 102.1384. 97% 2D-inc. calculated from HRMS.</p>
<p> Tert-butyl (pentyl-5-d)carbamate (2g)</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 4.68 (s, 1H), 3.11 (m, 2H), 1.48 (m, 2H), 1.44 (s, 9H), 1.30 (m, 4H), 0.95 – 0.84 (m, 2H). 82% D-inc. calculated from ¹H NMR. ¹³C NMR (100 MHz, CDCl₃) δ 155.99, 78.84, 40.55, 29.72, 28.91, 28.38, 22.32, 22.23, 13.95-13.46 (-CH₂-D). HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₀H₂₀DNO₂ 188.1635; Found 188.1643.</p>
<p> Decyl-10-d acetate (2h)</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 4.1 (t, <i>J</i> = 6.8 Hz, 2H), 2.0 (s, 3H), 1.6 (t, <i>J</i> = 7.1 Hz, 2H), 1.3 (d, <i>J</i> = 3.5 Hz, 14H), 0.9 – 0.8 (m, 2H). 85% D-inc. calculated from ¹H NMR. ¹³C NMR (100 MHz, CDCl₃) δ 171.30, 64.69, 31.90, 31.87, 29.54, 29.32, 29.27, 28.61, 25.92, 22.69, 22.60, 21.04, 14.12-13.63 (-CH₂-D). HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₁₂H₂₃DO₂ 201.1839; Found 201.1841.</p>
<p> Methyl octanoate-8-d (2i)</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 3.60 (s, 3H), 2.23 (t, <i>J</i> = 15.1 Hz, 2H), 1.59 – 1.51 (m, 2H), 1.25 – 1.14 (m, 8H), 0.85 – 0.76 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 173.38, 50.43, 33.11, 30.64, 30.61, 28.10, 27.91, 23.95, 21.49, 13.10-12.55 (-CH₂-D). HRMS (EI-TOF) m/z: [M]⁺ Calcd for C₉H₁₇DO₂ 159.1370; Found 159.1375. 93% D-inc. calculated from HRMS.</p>
<p> 1-dodec-1-ene-10-d</p>	<p>¹H NMR (400 MHz, CDCl₃) δ 5.82 (m, 1H), 5.10 – 4.87 (m, 2H), 2.12 – 1.97 (m, 2H), 1.37 (m, 2H), 1.27 (m, 10H), 0.88 (m, 2H).</p>

Dec-1-ene-10-d (2j)	¹³ C NMR (100 MHz, CDCl ₃) δ 139.31, 114.09, 33.84, 31.88, 29.49, 29.31, 29.18, 28.97, 22.60, 14.12-13.63 (-CH ₂ -D). HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₁₀ H ₁₉ D 141.1628; Found 141.1617. 92% D-inc. calculated from HRMS.
 1-(Methoxy-d)dodecane (2k)	¹ H NMR (400 MHz, CDCl ₃) δ 3.36 (m, 2H), 3.33 – 3.28 (m, 2H), 1.56 (m, 2H), 1.29 (s, 18H), 0.88 (t, J = 6.7 Hz, 3H). 95% D-inc. calculated from ¹ H NMR. ¹³ C NMR (100 MHz, CDCl ₃) δ 72.97, 58.47-58.04 (-OCH ₂ -D), 31.94, 29.65, 29.62, 29.53, 29.36, 26.16, 22.70, 14.13. HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₁₃ H ₂₇ DO 201.2203; Found 201.2219.
 Ethane-d (3a)	HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₂ H ₅ D 31.0532; Found 31.0558. 98% D-inc. calculated from HRMS.
 Hexane-1-d (3b)	HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₆ H ₁₃ D 87.1158; Found 87.1156. 97% D-inc. calculated from HRMS.
 1-Chlorobutane-4-d (3c)	HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₄ H ₈ DCl 93.0456; Found 93.0453. 83% D-inc. calculated from HRMS.
 2, 2, 4-Trimethylpentane-5-d (3d)	HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₈ H ₁₇ D 115.1471; Found 115.1475. 99% D-inc. calculated from HRMS.
 Butan-2-one-4-d (3e)	HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₄ H ₇ DO 73.0638; Found 73.0642. 92% D-inc. calculated from HRMS.
 Propane-1-d (3f)	HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₃ H ₇ D 45.0689; Found 45.0692. 88% D-inc. calculated from HRMS.
 But-1-ene-4-d (3g)	HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₄ H ₇ D 57.0689; Found 57.0689. 99% D-inc. calculated from HRMS.
 Isobutane-1-d (3h)	HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₄ H ₉ D 59.0845; Found 59.0847. 99% D-inc. calculated from HRMS.
 3-(Methoxy-d)heptane (4a)	¹ H NMR (400 MHz, CDCl ₃) δ 3.35 – 3.28 (m, 2H), 3.08 (m, 1H), 1.56 – 1.40 (m, 4H), 1.40 – 1.26 (m, 4H), 0.90 (q, J = 7.4, 7.0 Hz, 6H). 99% D-inc. calculated from ¹ H NMR. ¹³ C NMR (100 MHz, CDCl ₃) δ 82.07, 57.41-56.33 (-OCH ₂ -D), 53.45 (DCM), 32.70, 27.55, 25.82, 22.94, 14.13, 9.37. HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₈ H ₁₇ DO 131.1420; Found 131.1411.
 2-(Methoxy-d)octane (4b)	¹ H NMR (400 MHz, CDCl ₃) δ 3.34 – 3.20 (m, 3H), 1.54 – 1.45 (m, 2H), 1.28 (m, 8H), 1.12 (d, J = 6.1 Hz, 3H), 0.92 – 0.84 (t, 3H). 99% D-inc. calculated from ¹ H NMR. ¹³ C NMR (100 MHz, CDCl ₃) δ 76.87, 55.86-55.44 (-OCH ₂ -D), 53.44 (DCM), 36.36, 31.88, 29.46, 25.44, 22.64, 19.04, 14.11. HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₉ H ₁₉ DO 145.1577; Found 145.1581.

 <p>3-(Methoxy-d)oct-1-ene (4c)</p>	<p>$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 5.64 (ddd, $J = 16.9, 10.6, 7.8$ Hz, 1H), 5.25 – 5.09 (m, 2H), 3.48 (m, 1H), 3.30 – 3.19 (m, 2H), 1.60 – 1.38 (m, 2H), 1.37 – 1.19 (m, 6H), 0.88 (t, $J = 6.8$ Hz, 3H).</p> <p>93% D-inc. calculated from $^1\text{H NMR}$.</p> <p>$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 138.97, 117.04, 83.13, 56.14-55.64 ($-\text{OCH}_2\text{-D}$), 53.46 (DCM), 35.32, 31.84, 29.72, 24.99, 22.63, 14.08.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_9\text{H}_{17}\text{DO}$ 143.1420; Found 143.1425.</p>
 <p>2-(Methoxy-d)heptane (4d)</p>	<p>$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 3.37 – 3.20 (m, 3H), 1.59 – 1.36 (m, 2H), 1.29 (m, 6H), 1.12 (d, $J = 6.1$ Hz, 3H), 0.89 (t, $J = 6.8$ Hz, 3H).</p> <p>99% D-inc. calculated from $^1\text{H NMR}$.</p> <p>$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 76.87, 55.86-55.43 ($-\text{OCH}_2\text{-D}$), 36.31, 32.01, 25.15, 22.67, 19.04, 14.08.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_8\text{H}_{17}\text{DO}$ 131.1420; Found 131.1420.</p>
 <p>2-(Methoxy-d)-6-methylheptane (4e)</p>	<p>$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 3.32 – 3.29 (m, 3H), 1.57 – 1.48 (m, 2H), 1.26 (m, 5H), 1.12 (d, $J = 6.1$ Hz, 3H), 0.90 – 0.86 (m, 6H).</p> <p>97% D-inc. calculated from $^1\text{H NMR}$.</p> <p>$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 60.45, 55.89-55.45 ($-\text{OCH}_2\text{-D}$), 53.47 (DCM), 39.11, 36.57, 30.99, 27.99, 23.24, 22.62, 19.04.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_9\text{H}_{19}\text{DO}$ 145.1577; Found 145.1580.</p>
 <p>3-(Methoxy-d)-2-methylhexane (4f)</p>	<p>$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 3.37 – 3.28 (m, 2H), 2.93 – 2.83 (m, 1H), 1.91 – 1.76 (m, 1H), 1.48 – 1.29 (m, 4H), 0.90 (m, 9H).</p> <p>96% D-inc. calculated from $^1\text{H NMR}$.</p> <p>$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 86.10, 57.67-57.15 ($-\text{OCH}_2\text{-D}$), 53.44 (DCM), 40.95 (DMSO), 32.47, 30.31, 19.02, 18.17, 17.94, 14.36.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_8\text{H}_{17}\text{DO}$ 131.1420; Found 131.1429.</p>
 <p>3-(Methoxy-d3)heptane (4g)</p>	<p>$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 3.67 (m, 0.27H), 3.01 (m, 1H), 1.46 – 1.36 (m, 4H), 1.28 – 1.15 (m, 4H), 0.87 – 0.69 (m, 6H).</p> <p>98% D-inc. calculated from $^1\text{H NMR}$.</p> <p>$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 80.97, 54.68-54.26 ($-\text{OCD}_3$), 31.70, 26.53, 24.81, 21.93, 13.09, 8.34.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_8\text{H}_{15}\text{D}_3\text{O}$ 133.1546; Found 133.1544.</p>
 <p>2-(Methoxy-d3)octane (4h)</p>	<p>$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 3.28 (m, 1H), 1.59 – 1.36 (m, 2H), 1.28 (m, 8H), 1.12 (d, $J = 6.1$ Hz, 3H), 0.94 – 0.84 (m, 3H).</p> <p>94% D-inc. calculated from $^1\text{H NMR}$.</p> <p>$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 76.77, 55.24-54.81 ($-\text{OCD}_3$), 36.35, 31.87, 29.45, 25.43, 22.63, 19.03, 14.09.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_9\text{H}_{17}\text{D}_3\text{O}$ 147.1702; Found 147.1703.</p>
 <p>3-(Methoxy-d)oct-1-yne (4i)</p>	<p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_9\text{H}_{15}\text{DO}$ 141.1264; Found 141.1252.</p> <p>97% D-inc. calculated from HRMS.</p>
 <p>Octan-8-d-4-ol (4j)</p>	<p>$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 3.59 – 3.48 (m, 1H), 1.41 – 1.19 (m, 10H), 0.90 – 0.80 (m, 5H).</p> <p>92% D-inc. calculated from $^1\text{H NMR}$.</p> <p>$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 71.75, 39.66, 37.21, 27.85, 22.78, 18.75, 14.14-13.66</p>

	(-CH ₂ -D, -CH ₃). HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₈ H ₁₇ DO 131.1420; Found 131.1424.
 Undecan-1-d-4-ol (4k)	¹ H NMR (400 MHz, CDCl ₃) δ 3.60 (m, 1H), 1.43 (m, 6H), 1.29 (m, 10H), 0.88 (m, 5H). 83% D-inc. calculated from ¹ H NMR. ¹³ C NMR (100 MHz, CDCl ₃) δ 71.78, 39.65, 37.52, 31.85, 29.69, 29.32, 25.67, 22.67, 18.75, 14.11-13.65 (-CH ₂ -D, -CH ₃). HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₁₁ H ₂₃ DO 173.1890; Found 173.1899.
 (Propan-2-yl-1-d)benzene (5a)	¹ H NMR (400 MHz, CDCl ₃) δ 7.26 – 7.07 (m, 5H), 2.83 (m, 1H), 1.18 (m, 5H). ¹³ C NMR (100 MHz, CDCl ₃) δ 148.89, 128.32, 126.44, 125.77, 34.05, 24.00-23.53 (-CH ₂ -D, -CH ₃). HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₉ H ₁₁ D 121.1002; Found 121.1002. 93% D-inc. calculated from HRMS.
 (Propyl-2-d)benzene (5b)	¹ H NMR (400 MHz, CDCl ₃) δ 7.29-7.24 (m, 2H), 7.21-7.14 (m, 3H), 2.62 – 2.54 (d, 2H), 1.69 – 1.55 (m, 1H), 0.98 – 0.83 (d, 3H). 94% D-inc. calculated from ¹ H NMR. ¹³ C NMR (100 MHz, CDCl ₃) δ 142.75, 128.51, 128.25, 125.63, 38.03, 30.36, 24.64-24.06 (-CHD-), 13.79. HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₉ H ₁₁ D 121.1002; Found 121.0998.
 (Propyl-3-d)benzene (5c)	¹ H NMR (400 MHz, CDCl ₃) δ 7.31 – 7.23 (m, 2H), 7.22 – 7.12 (m, 3H), 2.62 – 2.54 (t, 2H), 1.71 – 1.57 (m, 2H), 0.92 (m, 2H). ¹³ C NMR (100 MHz, CDCl ₃) δ 140.87, 126.63, 126.37, 123.76, 36.22, 22.68, 12.01-11.52 (-CH ₂ -D). HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₉ H ₁₁ D 121.1002; Found 121.0999. 96% D-inc. calculated from HRMS.
 1-Phenyl-1-propanone-3-d (5d)	¹ H NMR (400 MHz, CDCl ₃) δ 7.95 – 7.79 (m, 2H), 7.51 – 7.41 (m, 1H), 7.37 (m, 2H), 3.08 – 2.71 (m, 2H), 1.17 – 1.08 (m, 2H). 86% D-inc. calculated from ¹ H NMR. ¹³ C NMR (100 MHz, CDCl ₃) δ 199.90, 135.88, 131.87, 127.53, 126.96, 30.75, 7.21-6.76 (-CH ₂ -D). HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₉ H ₉ DO 135.0794; Found 135.0801.
 1-(4-Fluorophenyl)butan-1-one-4-d (5e)	¹ H NMR (400 MHz, CDCl ₃) δ 7.99 (dd, J = 8.7, 5.6 Hz, 2H), 7.12 (t, J = 8.6 Hz, 2H), 2.92 (t, J = 7.3 Hz, 2H), 1.84 – 1.69 (m, 2H), 1.09 – 0.93 (m, 2H). 87% D-inc. calculated from ¹ H NMR. ¹³ C NMR (100 MHz, CDCl ₃) δ 198.82, 166.91, 164.38, 133.55, 133.52, 130.70, 130.61, 128.84, 128.76, 115.73, 115.51, 40.41, 17.66, 13.86-13.37 (-CH ₂ -D). HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₁₀ H ₁₀ DOF 167.0857; Found 167.0863.
 Methylcyclohexane-1-d (5f)	HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₇ H ₁₃ D 99.1158; Found 99.1188. 97% D-inc. calculated from HRMS.
 (Methyl-d)cyclohexane (5g)	HRMS (EI-TOF) m/z: [M] ⁺ Calcd for C ₇ H ₁₃ D 99.1158; Found 99.1161. 90% D-inc. calculated from HRMS.

 <p>1,4-dimethyl-2-((4-methylpentyl-4-d)oxy)benzene (5h), from Gemfibrozil.</p>	<p>$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.00 (d, $J = 7.4$ Hz, 1H), 6.69 – 6.60 (m, 2H), 3.92 (t, $J = 6.5$ Hz, 2H), 2.31 (s, 3H), 2.18 (s, 3H), 1.85 – 1.73 (m, 2H), 1.43 – 1.29 (m, 2H), 0.92 (s, 6H).</p> <p>91% D-inc. calculated from $^1\text{H NMR}$.</p> <p>$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 157.15, 136.46, 130.27, 123.65, 120.55, 112.01, 68.18, 53.46, 35.20, 27.80-27.11 ($-\underline{\text{C}}-\text{D}$, $-\underline{\text{C}}-\text{H}$), 22.62, 22.49, 21.44, 15.82.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_{14}\text{H}_{21}\text{DO}$ 207.1733; Found 207.1736.</p>
 <p>(E)-7-hydroxy-5-methoxy-4-methyl-6-(3-methylpent-2-en-1-yl-5-d)isobenzofuran-1(3H)-one (5i), from Mycophenolic acid.</p>	<p>$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.67 (s, 1H), 5.20 (s, 2H), 5.21 – 5.14 (m, 1H), 3.77 (s, 3H), 3.40 (d, $J = 6.9$ Hz, 2H), 2.15 (s, 3H), 1.98 (t, $J = 7.4$ Hz, 2H), 1.79 (s, 3H), 1.01 – 0.90 (m, 2H).</p> <p>91% D-inc. calculated from $^1\text{H NMR}$.</p> <p>$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 173.02, 163.73, 153.72, 143.89, 137.78, 122.66, 120.42, 116.72, 106.38, 70.07, 61.03, 32.28, 22.59, 16.15, 12.50-12.15 ($-\underline{\text{C}}\text{H}_2-\text{D}$, $-\underline{\text{C}}\text{H}_3$), 11.59.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_{16}\text{H}_{19}\text{DO}_4$ 277.1424; Found 277.1423.</p>
 <p>2-(ethyl-1-d)dibenzof[b,f]thiepin-10(11H)-one (5j), from Zaltoprofen.</p>	<p>$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.19 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.59 (dd, $J = 7.9, 1.3$ Hz, 1H), 7.54 (d, $J = 7.9$ Hz, 1H), 7.41 (td, $J = 7.6, 1.7$ Hz, 1H), 7.35 – 7.24 (m, 2H), 7.03 (dd, $J = 7.9, 2.0$ Hz, 1H), 4.34 (s, 0.67 H), 2.69 – 2.56 (m, 1H), 1.32 – 1.17 (d, 3H).</p> <p>93% D-inc. calculated from $^1\text{H NMR}$.</p> <p>$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 191.78, 146.66, 140.71, 137.51, 136.18, 132.43, 131.51, 131.32, 131.19, 130.78, 128.94, 126.79, 126.69, 51.06-50.52 ($-\text{C}(\text{O})-\underline{\text{C}}-\text{D}_2$, $-\text{C}(\text{O})-\underline{\text{C}}\text{H}-\text{D}$, $-\text{C}(\text{O})-\underline{\text{C}}\text{H}_2$), 28.54 - 28.01 ($-\underline{\text{C}}\text{H}-\text{D}$, $-\underline{\text{C}}\text{H}_2-$), 15.42, 15.34.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_{16}\text{H}_{11}\text{D}_3\text{OS}$ 257.0964; Found 257.0916.</p>
 <p>(4aS, 10aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-d (5k), from Dehydroabietic acid.</p>	<p>$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.16 (d, $J = 8.1$ Hz, 1H), 6.99 (dd, $J = 8.2, 2.1$ Hz, 1H), 6.89 (s, 1H), 2.88 (td, $J = 7.0, 2.1$ Hz, 2H), 2.84 – 2.76 (m, 1H), 2.28 – 2.15 (m, 1H), 2.02 – 1.88 (m, 1H), 1.85 – 1.69 (m, 2H), 1.68 (dd, $J = 12.8, 2.3$ Hz, 1H), 1.56 (tt, $J = 10.0, 2.4$ Hz, 3H), 1.48 (dtd, $J = 15.3, 5.6, 4.7, 2.5$ Hz, 1H), 1.38 (td, $J = 13.2, 3.6$ Hz, 1H), 1.23 (d, $J = 7.0, 1.8$ Hz, 6H), 1.17 (s, $J = 0.8$ Hz, 3H), 0.99 (s, 3H).</p> <p>90% D-inc. calculated from $^1\text{H NMR}$.</p> <p>$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 147.19, 145.45, 135.11, 127.00, 124.33, 123.83, 44.35, 38.62, 37.26, 33.48, 32.97, 30.38, 25.59, 24.55, 24.04, 24.02, 22.81-20.41 ($-\underline{\text{C}}-\text{D}$, $-\underline{\text{C}}-\text{H}$), 18.07, 15.05.</p> <p>HRMS (EI-TOF) m/z: $[\text{M}]^+$ Calcd for $\text{C}_{19}\text{H}_{27}\text{D}$ 257.2254; Found 257.2258.</p>

Supplementary References

1. Xu, J., Arkin, M., Peng, Y. Z., Xu, W. H., Yu, H. L., Lin, X. F., Wu, Q. Enantiocomplementary decarboxylative hydroxylation combining photocatalysis and whole-cell biocatalysis in a one-pot cascade process. *Green Chem* **21**, 1907-1911 (2019).
2. Bagutski, V., Elford, T.G., Aggarwal, V.K. Synthesis of highly enantioenriched C-tertiary amines from boronic esters: application to the synthesis of Igmesine. *Angew. Chem. Int. Edit.* **50**, 1080-1083 (2011).